



Investment and Exit

Motilal Oswal PE bets on Molbio Diagnostics in new healthcare bet

5th March 2020. VCCircle

Motilal Oswal Private Equity (MOPE), a subsidiary of diversified financial services group Motilal Oswal Financial Services Ltd, has agreed to invest up to Rs 240 crore (approximately \$32.75 million at current exchange rates) in Molbio Diagnostics Pvt. Ltd... [more](#)

Tricog raises \$10.5 million in Series B Funding

3rd March 2020. Express Healthcare

Analytics firm Tricog has raised \$10.5 million in Series B funding round from UTEC - The University of Tokyo Edge Capital, Japan; Aflac Ventures, Japan; TeamFund, USA and Dream Incubator, Japan. Existing investors Inventus Capital and Blume Ventures also participated in this round.... [more](#)

OrbiMed floats fourth Asia healthcare PE fund

9th March 2020. VCCircle

Healthcare-focused investment firm OrbiMed has launched its fourth Asia private equity fund, which is larger than its previous funds.... [more](#)

Merger and Acquisition

Asia Healthcare in talks to buy Cloudnine stake

3rd March 2020. Economic Times

TPG Growth-backed Asia Healthcare Holdings (AHH) has held early discussions to acquire a significant stake in maternity and childcare hospital chain Cloudnine... [more](#)

Pharma

Zydus Cadila gets DCGI nod for world's first drug to treat liver disease

6th March 2020. ET Health World

Pharmaceutical major Zydus Cadila on Thursday said it has received Drug Controller General of India (DCGI) approval for its new drug application for Saroglitazar to treat a particular condition of liver, commonly known as NASH in India... [more](#)

Strides Pharma Science gets USFDA nod for generic anti-bacterial capsules

4th March 2020. ET Health World

Strides Pharma Science on Wednesday said it has received approval from the US health regulator for its generic tetracycline hydrochloride capsules used for treatment of many bacterial infections... [more](#)

HealthCare

Cabinet approves MoU between India and Cote d'Ivoire for cooperation in the field of Health

5th March 2020. IBEF

The Union Cabinet has approved a Memorandum of Understanding (MoU) between Ministry of Health and Family Welfare of the Republic of India and the Ministry of Health and Public Hygiene of the Republic of Cote d'Ivoire on Cooperation in the field of Health... [more](#)

Biotech

USFDA accepts Mylan's Biologics License Application

9th March 2020. IIFL

Biocon Ltd. and Mylan today announced that the U.S. Food and Drug Administration (USFDA) has accepted Mylan's Biologics License Application (BLA), a proposed biosimilar to Avastin (bevacizumab), for review under the 351(k) pathway... [more](#)

Serum Institute collaborates with Novavax for malaria vaccine

13th March 2020. Bio Spectrum

US based Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII) have announced a commercial license agreement for the use of Novavax' proprietary Matrix-M™ vaccine adjuvant with SII's malaria vaccine... [more](#)

Global News

AbbVie gets final EU approval for Allergan acquisition

3rd March 2020. The Pharma Letter

As part of US biopharma major AbbVie's \$6.3 billion acquisition of Ireland-incorporated Allergan... [more](#)

Akouos nabs meaty \$105M raise, adds VC and biotech veterans to board

4th March 2020. Fierce Biotech

Boston-based hearing loss gene therapy biotech Akouos has grabbed a \$105 million series B funding round.... [more](#)

Amunix raises \$73M to take T-cell engager into humans

4th March 2020. Fierce Biotech

Amunix Pharmaceuticals has raised \$73 million in series A funding. The Omega Funds-led round sets Amunix up to move its lead T-cell engager into the clinic after years of licensing its half-life extension technology to leading drug developers... [more](#)

Gilead strikes \$4.9B Forty Seven acquisition, paying a hefty premium for cancer drug

2nd March 2020. Fierce Biotech

Gilead has struck a deal to buy Forty Seven for \$4.9 billion. The takeover will give Gilead control of midphase anti-CD47 antibody magrolimab that delivered data that impressed investors late last year... [more](#)

Best Regards



Pooja Shah

Head-Research

Monal Capital (P) Limited

Tel.: +91-22-4976 1501 | 4976 1601 | 47081900 Mobile: +91 84548 07250 | [Email: pooja@monalcapital.com](mailto:pooja@monalcapital.com)

114, The Summit business bay, W.E. Highway Metro station, Opp.PVR, Off Andheri Kurla Road, Andheri (E) , Mumbai : 400 093 India, [Website: www.monalcapital.com](http://www.monalcapital.com)

[Investment Banking - Debt Syndication](#) | [Corporate Finance](#) | [Bonds](#) | [Equity](#) | [Infrastructure](#) | [Real Estate](#) | [M&A](#) | [Stress Asset Solutions](#) | [Startup & VC Advisory](#)

Disclaimer: Information gathered & material used in this document is believed to be from reliable sources. Monal Capital however does not warrant the accuracy, reasonableness and/or completeness of any information. Monal Capital and any of its officers directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner